Invion engages Numoda Corporation for clinical trial management services for INV102 and INV103 phase II clinical trials
– Numoda Capital Innovations, LLC to invest in Invion via private placements and open market purchases
BRISBANE, 20 DECEMBER 2012: Australian drug development company Invion Limited (ASX:IVX) today announced that it has entered into a strategic alliance with leading provider of global clinical trial technologies and services, Numoda Corporation and its affiliate, Numoda Capital Innovations, LLC.
NCI’s total commitment under the agreement is for an investment of up to $2 million to occur across current and future clinical trials. The alliance provides Invion access to Numoda’s TruPoints technology which will organize the due diligence material coming from Invion’s forthcoming clinical trials in smoking cessation and lupus. The patented technology will enable Invion to facilitate the flow of business, contract manufacturing and “live” clinical trial information to potential collaborative and commercial partners without incurring a statistical penalty.
IVX Price at posting:
2.1¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)